Enochian Biosciences Inc logo

ENOB

Enochian Biosciences Inc

$2.44

Earnings Summary

Revenue
$0Mn
Net Profits
$-6.2Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Enochian Biosciences Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Enochian Biosciences Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Enochian Biosciences Inc’s net profit fell -53.86% since last year same period to $-6.2Mn in the Q1 2022. On a quarterly growth basis, Enochian Biosciences Inc has generated 5.79% jump in its net profits since last 3-months.

Net Profit Margins:

Enochian Biosciences Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Enochian Biosciences Inc has generated NaN% jump in its net profit margins since last 3-months.

Key Ratios

Key ratios of the Enochian Biosciences Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.12
Return on Assets (ROA)
-0.11
Return on Equity (ROE)
-0.25
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Enochian Biosciences Inc’s earning per share (EPS) jumped 64.57% since last year same period to -0.12 in the Q1 2022. This indicates that the Enochian Biosciences Inc has generated 64.57% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Enochian Biosciences Inc’s return on assets (ROA) stands at -0.11.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Enochian Biosciences Inc’s return on equity (ROE) stands at -0.25.

Dividend Per Share (DPS):

Enochian Biosciences Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Company Information

Enochian BioSciences is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy. Our gene-modified cell therapy platform can be applied to multiple indications including HIV/AIDS, HBV and Oncology.

Organisation
Enochian Biosciences Inc
Employees
10
Industry
Finance